Souhaitez-vous accéder aux communiqués récents ?

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase...

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with...

1Q26 Earnings release: VPG revenue grew year over year and sequentially; bookings of $102.1 million increased 29% sequentially.

(In United States dollars, except where noted otherwise) TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) today announces the...

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and...

Key Q1 2026 Highlights Revenue: $723M, down 3.7%. Growth in Government and Transportation segmentsPre-tax Income (Loss): $(27)M, improved by $29M year-over-yearAdj. EBITDA(1): $49M, improved by $12M...

Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety  SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today...

Reiterates Full Year 2026 Outlook Net Loss of $70.3 Million for the First QuarterConsolidated Revenue and Adjusted EBITDA of $987.5 Million and $441.6 Million, Respectively, for the First Quarter ...

RA'ANANA, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies," or the "Company"), today issued a letter to its...

Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on...